Method Profile
Compare organoid viability, membrane damage, proliferation-associated staining and cAMP-pathway responses after PPTN exposure.
Exploratory pharmacological assessment of a P2Y14-antagonist hypothesis in a cervical cancer culture model.
Supplied cervical cancer organoids, with HeLa and SiHa cell-line experiments providing parallel evidence. A donor cohort size is not stated.
Organoid PPTN exposure for 72 hours; dose-response IC50 and 17 μM follow-up treatment. Cell-line conditions are separately specified.
Biological models
AimingMed-supplied cervical cancer organoids; HeLa and SiHa cell lines.
Readouts
Luminescent organoid viability, LDH release, Ki67/CK13 immunofluorescence, cAMP ELISA and PKA/CREB immunoblotting.
Viability, membrane damage, proliferation/differentiation markers and signaling are assessed separately against same-passage control cultures.
PPTN dose-response followed by organoid endpoint comparison at 17 μM for 72 hours.
Cervical cancer organoid cultures; endpoint assays report n = 3 samples per group. The organoid donor count is not stated.
Matched untreated/control organoids; HeLa and SiHa experiments analyzed separately.
Organoid IC50 was 34.88 μM at 72 hours. PPTN reduced viability and Ki67 staining, increased LDH release, cAMP levels and PKA/CREB phosphorylation, without an obvious CK13 change.
The P2Y14 receptor antagonist PPTN reduced growth and increased membrane-damage measurements in cervical cancer cells and organoids. Higher cAMP and PKA/CREB phosphorylation accompanied the response, while CK13 staining remained unchanged.
